Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors cautious. See why ATYR stock is a Hold.

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

Atyr PHARMA (NASDAQ:ATYR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

In a challenging economic environment, ZURA's stock has hit a 52-week low, dropping to $1.75. According to InvestingPro ...

If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday ...

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $22.00. Pick the best stocks and ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company, is garnering attention from investors and analysts alike as it advances its lead candidate, efzofitimod, through late-stage ...

Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact [email protected]. About aTyr aTyr is a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company, is garnering attention from investors and analysts alike as it advances its lead candidate, efzofitimod, through late-stage ...